Protein Kinase Therapeutics in Oncology - Where to Commercialize? : Market Research Report

Protein Kinase Therapeutics in Oncology - Where to Commercialize?

Published: Oct. 29, 2009 - 1,442 Pages

1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 Table of Contents: 4.1 List of Figures; 4.2 List of Tables
5 Introduction: 5.1 The Scope of this Report; 5.2 Definitions; 5.3 Abbreviations
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment: 6.1 Drug Repositioning in Oncology; 6.2 Introduction to Protein Kinase Therapeutic Targets in Oncology; 6.3 The Cancer Genome Project and Protein Kinase Therapeutic Targets in Oncology; 6.3.1 Protein Kinase Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer; 6.4 Structure-based Drug Design in Protein Kinase Therapeutics is Stimulated by Available Structure Data on Biological Targets; 6.5 Target-Target Interactions among Identified Protein Kinase Therapeutics Targets in Oncology; 6.6 The Drug-Target Interactome; 6.7 Protein Expression Levels of Identified Protein Kinase Therapeutic Targets in Oncology; 6.8 Pathway Analysis of Cancer Protein Kinase Therapeutic Targets
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline?: 7.1 Terminated Drug Target Profiles of Cancer Protein Kinase Drugs; 7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology; 7.3 Phase III Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology; 7.4 Phase II Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology; 7.5 Phase I Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology; 7.6 Preclinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology; 7.7 Development Profiles of All Protein Kinase Drugs in Oncology
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type: 8.1 Small Molecules; 8.2 Peptide/Protein Drugs; 8.3 Antibodies and Antibody-like Structures; 8.4 Nucleic Acid Therapies; 8.5 Cell and Gene Therapy; 8.6 The Competition Through Close Mechanistic Approximation of Cancer Protein Kinase Therapeutics; 8.7 Compound Strategies based on Sub-Cellular Localization of Protein Kinase Drug Targets in Oncology
9 Selecting Cancer Indications for Protein Kinase Therapeutics: 9.1 Acute Lymphocytic Leukemia; 9.2 Acute Myelogenous Leukemia; 9.3 Adrenal Cancer; 9.4 B-cell Lymphoma; 9.5 Basal Cell Cancer; 9.6 Benign prostatic hyperplasia; 9.7 Biliary Cancer; 9.8 Bladder Cancer; 9.9 Bone Cancer; 9.10 Brain Cancer; 9.11 Breast Cancer; 9.12 Carcinoid; 9.13 Cervical Cancer; 9.14 Chronic Lymphocytic Leukemia; 9.15 Chronic Myelogenous Leukemia; 9.16 Colorectal Cancer; 9.17 Endometrial Cancer; 9.18 Fallopian Tube Cancer; 9.19 Gastrointestinal Cancer (general); 9.20 Gastrointestinal Stomach Cancer; 9.21 Gastrointestinal Stromal Cancer; 9.22 Head and Neck Cancer; 9.23 Hodgkin's Lymphoma; 9.24 Leiomyo Sarcoma; 9.25 Leukemia (general); 9.26 Lipo Sarcoma; 9.27 Liver Cancer; 9.28 Lung Cancer (general); 9.29 Lymphoma (general); 9.30 Mast Cell Leukemia; 9.31 Melanoma; 9.32 Mesothelioma; 9.33 Myelodysplastic Syndrome; 9.34 Myeloma; 9.35 Nasopharyngeal Cancer; 9.36 Neuroblastoma Cancer; 9.37 non-Hodgkin's Lymphoma; 9.38 Non-Small Cell Lung Cancer; 9.39 Oesophageal Cancer; 9.40 Oral Cancer; 9.41 Osteo Sarcoma; 9.42 Ovarian Cancer; 9.43 Pancreatic Cancer; 9.44 Peritoneal Cancer; 9.45 Prostate Cancer; 9.46 Renal Cancer; 9.47 Rhabdomyo Sarcoma; 9.48 Sarcoma (general); 9.49 Small Cell Lung Cancer; 9.50 Soft Tissue Sarcoma; 9.51 Squamous Cell Cancer; 9.52 Synovial Sarcoma; 9.53 T-cell Lymphoma; 9.54 Testicular Cancer; 9.55 Thymoma Cancer; 9.56 Thyroid Cancer; 9.57 Unspecified Cancer Indication
10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator: 10.1 4SC; 10.2 AB Science; 10.3 Abbott; 10.4 Abiogen; 10.5 Abraxis BioScience; 10.6 Advenchen; 10.7 AEgera; 10.8 Aeterna Zentaris; 10.9 Aida Pharmaceuticals; 10.10 Alethia Biotherapeutics; 10.11 Alfacell; 10.12 AlphaVax; 10.13 Ambit Biosciences; 10.14 Amgen; 10.15 Amphora; 10.16 Apthera; 10.17 Ariad; 10.18 Arno Therapeutics; 10.19 ArQule; 10.20 Array BioPharma; 10.21 Astellas; 10.22 Astex Therapeutics; 10.23 AstraZeneca; 10.24 Avalon; 10.25 Bayer; 10.26 Benitec; 10.27 Berkeley Lab; 10.28 BioAxone; 10.29 Biotecnol; 10.30 Biotica Technology; 10.31 Boehringer Ingelheim; 10.32 Bristol-Myers Squibb; 10.33 BTG; 10.34 Calistoga Pharmaceuticals; 10.35 Callisto Pharmaceuticals; 10.36 Cambrex; 10.37 CanBas; 10.38 Cancer Research Technology; 10.39 Catalyst Biosciences; 10.40 Celgene; 10.41 Cell Therapeutics; 10.42 Cephalon; 10.43 Chroma Therapeutics; 10.44 CompleGen; 10.45 Compugen; 10.46 CoNCERT Pharmaceuticals; 10.47 Curis; 10.48 Cyclacel; 10.49 Cylene Pharmaceuticals; 10.50 Cytokine PharmaSciences; 10.51 Cytopia; 10.52 Dainippon Sumitomo Pharma; 10.53 Deciphera Pharmaceuticals; 10.54 DeveloGen; 10.55 Dyax; 10.56 Eisai; 10.57 Elara Pharmaceuticals; 10.58 Eli Lilly; 10.59 Enkam Pharmaceuticals; 10.60 EntreMed; 10.61 Exelixis; 10.62 Galapagos; 10.63 Genentech; 10.64 Generex; 10.65 GlaxoSmithKline; 10.66 GlycoGenesys; 10.67 GPC Biotech; 10.68 Hanmi; 10.69 Hoffmann-La Roche; 10.70 Hutchison China MediTech; 10.71 Idera Pharmaceuticals; 10.72 ImClone Systems; 10.73 ImmunoFrontier; 10.74 Incyte Corporation; 10.75 Inhibiton Therapeutics; 10.76 Inovio; 10.77 Insmed; 10.78 InterMune; 10.79 ISU ABXIS; 10.80 Johnson & Johnson; 10.81 KAI Pharmaceuticals; 10.82 Kalypsys; 10.83 Keryx Biopharmaceuticals; 10.84 Kiadis; 10.85 Kirin Pharma; 10.86 KuDOS; 10.87 Kyowa Hakko Kirin; 10.88 Lexicon Pharmaceuticals; 10.89 Locus Pharmaceuticals; 10.90 Lorus Therapeutics; 10.91 MaxoCore Pharmaceuticals; 10.92 Medisyn Technologies; 10.93 Merck & Co; 10.94 MethylGene; 10.95 Mitsubishi Tanabe Pharma; 10.96 Molecular LogiX; 10.97 NeoPharm; 10.98 Nerviano Medical Sciences; 10.99 NicOx; 10.100 Nidus Laboratories; 10.101 NIH - The US National Institute of Health; 10.102 Nippon Shinyaku; 10.103 Non-industrial Source; 10.104 Novartis; 10.105 Novogen; 10.106 Oncalis; 10.107 Onconova; 10.108 OncoTherapy Science; 10.109 Oncothyreon; 10.110 OSI Pharmaceuticals; 10.111 Pathway Therapeutics; 10.112 Peregrine Pharmaceuticals; 10.113 Pfizer; 10.114 Pharmacyclics; 10.115 PharmaGap; 10.116 PharmaMar; 10.117 Pharmexa; 10.118 Phytomedics; 10.119 Piramal; 10.120 PIramed; 10.121 Plexxikon; 10.122 Provid; 10.123 QLT; 10.124 Quantum Pharmaceuticals; 10.125 Ras Therapeutics; 10.126 Reata Pharmaceuticals; 10.127 Receptor BioLogix; 10.128 Rexahn; 10.129 Rigel; 10.130 Sanofi-Aventis; 10.131 Sareum; 10.132 SBIO; 10.133 Scancell; 10.134 Schering-Plough; 10.135 Semafore Pharmaceuticals; 10.136 Sentinel Oncology; 10.137 SGX Pharmaceuticals; 10.138 Silence Therapeutics; 10.139 Sirna Therapeutics; 10.140 Sunesis; 10.141 SuperGen; 10.142 Supratek Pharma; 10.143 Switch Pharma; 10.144 Takeda; 10.145 Targa Therapeutics; 10.146 TargeGen; 10.147 Tekmira Pharmaceuticals; 10.148 Telik; 10.149 Thallion Pharmaceuticals; 10.150 Theryte; 10.151 ToolGen; 10.152 TopoTarget; 10.153 UCB; 10.154 VasGene Therapeutics; 10.155 Velacor Therapeutics; 10.156 Vertex Pharmaceuticals; 10.157 ViroMed; 10.158 Wyeth; 10.159 Xcovery; 10.160 Xencor
11 Disclaimer
12 Drug Index
13 Company Index
4.1 List of Figures: Figure 1: Visualization of Target-Target Interactions among Protein Kinase Drug Targets in Oncology; Figure 2: The Drug-Protein Interactome of Protein Kinase Drugs -Clusters I; Figure 3: The Drug-Protein Interactome of Protein Kinase Drugs - Clusters II; Figure 4: Head-to-Head Targeting Interactome of Protein Kinase Drugs; Figure 5: Distribution of Compound Types among Protein Kinase Drugs in Oncology; Figure 6: Primary Sub-cellular Localization of Drug Targets
4.2 List of Tables: Table 1: Competitive Pressure Force among Protein Kinase Drugs in Oncology; Table 2: Overall Breakdown of the Included Protein Kinase Pipeline by Cancer Indication and Stage of Development; Table 3: Overview of Drug Target Profile Themes; Table 4: Terminally Ceased Therapeutic Protein Kinase Targets in Oncology; Table 5: Drug Targets of Protein Kinase Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census; Table 6: Identity of Protein Kinase Drug Targets with Available Biological Structures; Table 7: Number of Target-Target Interactions among Protein Kinase Drug Targets in Oncology; Table 8: Drug-Protein Interactome Clusters; Table 9: Protein Kinase Drug Targets with Available Protein Expression Profiles; Table 10: Pathway Summary; Table 11: Drug Targets without any Identified Assigned Pathways; Table 12: Pathway Profiles According to BioCarta of Protein Kinase Drug Targets in Oncology; Table 13: Pathway Profiles According to KEGG of Protein Kinase Drug Targets in Oncology; Table 14: Pathway Profiles According to NetPath of Protein Kinase Drug Targets in Oncology; Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness; Table 16: Top Competitive Protein Kinase Target Profiles in Oncology; Table 17: Terminated Drug Target Strategies of Protein Kinase Drugs in Oncology; Table 18 New and Unique Protein Kinase Target Strategies in Cancer Currently in Pre-Registration to Marketed; Table 19: The Competition Through Close Mechanistic Approximation Between Marketed Protein Kinase Drugs in Oncology; Table 20: New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase III Clinical Development; Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Protein Kinase Drugs in Oncology; Table 22: New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase II Clinical Development; Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Protein Kinase Drugs in Oncology; Table 24 New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase I Clinical Development; Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Protein Kinase Drugs in Oncology; Table 26: New and Unique Protein Kinase Target Strategies in Oncology Currently in Preclinical Development; Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Protein Kinase Drugs in Oncology; Table 28: The Progression, Maturity and Competitive Comparison of Protein Kinase Drug Target Profiles in Cancer Drug Development; Table 29: Overview of Compound Strategy Competition Among Protein Kinase Drugs in Oncology; Table 30: Overview of the Competitive Landscape of Small Molecular Protein Kinase Drugs in Oncology; Table 31: Head-to-Head Target Competition Between Small Molecule Protein Kinase Drugs for the Treatment of Cancer; Table 32: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs of Protein Kinase Therapeutics in Oncology; Table 33: The Progression, Maturity and Competitive Comparison of Target Profiles of Small Molecule Protein Kinase Drugs in Development; Table 34: Overview of the Competitive Landscape of Peptide Based Protein Kinase Drugs in Oncology; Table 35: The Progression, Maturity and Competitive Comparison of Target Profiles of Peptide Based Protein Kinase Drugs in Development; Table 36: Overview of the Competitive Landscape of Protein Based Protein Kinase Drugs in Oncology; Table 37: The Competition Through Close Mechanistic Approximation Between Protein Based Protein Kinase Drugs in Oncology; Table 38: The Progression, Maturity and Competitive Comparison of Protein Based Protein Kinase Drugs in Development; Table 39: Overview of the Competitive Landscape of Antibody Protein Kinase Drugs in Oncology; Table 40: The Competition Through Close Mechanistic Approximation Between Antibody Protein Kinase Drugs in Oncology; Table 41: The Progression, Maturity and Competitive Comparison of Target Profiles of Antibody Protein Kinase Drugs in Development; Table 42: Overview of the Competitive Landscape of Nucleic Acid Therapy Protein Kinase Drugs in Oncology; Table 43: The Competition Through Close Mechanistic Approximation Between Nucleic Acid Therapy Protein Kinase Drugs in Oncology; Table 44: The Progression, Maturity and Competitive Comparison of Target Profiles of Nucleic Acid Protein Kinase Drugs in Development; Table 45: Potential Forms of Cell Therapy; Table 46: Vectors in Gene Therapy; Table 47: The Progression, Maturity and Competitive Comparison of Target Profiles of Cell Therapy Based Protein Kinase Drugs in Development; Table 48: Overview of the Competitive Landscape of Gene Therapy Protein Kinase Drugs in Oncology; Table 49: The Progression, Maturity and Competitive Comparison of Target Profiles of Gene Therapy Based Protein Kinase Drugs in Development; Table 50: The Competition Through Close Mechanistic Approximation Among All Protein Kinase Drugs in Oncology; Table 51: Compound Strategies based on Sub-Cellular Localization of Protein Kinase Drug Targets in Oncology; Table 52: Competitive Summary of Protein Kinase Drugs by Cancer Indication; Table 53: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Acute Lymphocytic Leukemia; Table 54: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs; Table 55: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Acute Myelogenous Leukemia; Table 56: The Competition through Close Mechanistic Approximation between Acute Myelogenous Drugs; Table 57: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Adrenal Cancer; Table 58: Drug Target Profiles of Protein Kinase Drugs for the Treatment of B-cell Lymphoma; Table 59: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs; Table 60: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Basal Cell Cancer; Table 61: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Benign Prostatic Hyperplasia; Table 62: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Biliary Cancer; Table 63: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Bladder Cancer; Table 64: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs; Table 65: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Bone Cancer; Table 66: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Brain Cancer; Table 67: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs; Table 68: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Breast Cancer; Table 69: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs; Table 70: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Carcinoid; Table 71: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Cervical Cancer; Table 72: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs; Table 73: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Chronic Lymphocytic Leukemia; Table 74: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs; Table 75: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Chronic Myelogenous Leukemia 530; Table 76: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs; Table 77: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Colorectal Cancer; Table 78: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs; Table 79: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Endometrial Cancer; Table 80: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Fallopian Tube Cancer; Table 81: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs 544; Table 82: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Cancer (general); Table 83: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs; Table 84: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stomach Cancer; Table 85: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer
Drugs; Table 86: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stromal Cancer 549; Table 87: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs; Table 88: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Head and Neck Cancer; Table 89: The Competition through Close Mechanistic Approximation between Head and Neck and Cancer Drugs; Table 90: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Hodgkin's Lymphoma; Table 91: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Leiomyo Sarcoma; Table 92: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Leukemia (general); Table 93: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lipo Sarcoma; Table 94: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Liver Cancer; Table 95: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs; Table 96: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lung Cancer (general); Table 97: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 563; Table 98: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lymphoma (general); Table 99: The Competition through Close Mechanistic Approximation between Lymphoma (general) Drugs; Table 100: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Mast Cell Leukemia; Table 101: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Melanoma; Table 102: The Competition through Close Mechanistic Approximation between Melanoma Cancer Drugs; Table 103: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Mesothelioma; Table 104: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs; Table 105: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Myelodysplastic Syndrome; Table 106: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs; Table 107: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Myeloma; Table 108: The Competition through Close Mechanistic Approximation between Myeloma Drugs; Table 109: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Nasopharyngeal Cancer; Table 110: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Neuroblastoma Cancer; Table 111: Drug Target Profiles of Protein Kinase Drugs for the Treatment of non-Hodgkin's Lymphoma; Table 112: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs; Table 113: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Non-Small Cell Lung Cancer; Table 114: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drug; Table 115: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Oesophageal Cancer; Table 116: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 591; Table 117: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Oral Cancer; Table 118: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Osteo Sarcoma; Table 119: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Ovarian Cancer; Table 120: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs; Table 121: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Pancreatic Cancer; Table 122: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs; Table 123: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Peritoneal Cancer; Table 124: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs; Table 125: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Prostate Cancer; Table 126: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs; Table 127: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Renal Cancer; Table 128: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs; Table 129: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Rhabdomyo Sarcoma; Table 130: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Sarcoma (general); Table 131: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs; Table 132: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Small Cell Lung Cancer; Table 133: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs; Table 134: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Soft Tissue Sarcoma; Table 135: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Squamous Cell Cancer; Table 136: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Synovial Sarcoma; Table 137: Drug Target Profiles of Protein Kinase Drugs for the Treatment of T-cell Lymphoma; Table 138: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Testicular Cancer; Table 139: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Thymoma Cancer; Table 140: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Thyroid Cancer; Table 141: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs; Table 142: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Unspecified Cancer Indication; Table 143: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs; Table 144: 4SC's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 145: AB Science's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 146: Abbott's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 147: Abiogen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 148: Abraxis BioScience's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 149: Advenchen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 150: AEgera's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 151: Aeterna Zentaris’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 152: Aida Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 153: Alethia Biotherapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 154: Alfacell's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 155: AlphaVax's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 156: Ambit Biosciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 157: Amgen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 158: Amphora's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 159: Apthera's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 160: Ariad's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 161: Arno Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 162: ArQule's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 163: Array BioPharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 164: Astellas’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 165: Astex Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 166: AstraZeneca's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 167: Avalon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 168: Bayer's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 169: Benitec's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 170: Berkeley Lab's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 171: BioAxone's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 172: Biotecnol's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 173: Biotica Technology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 174: Boehringer Ingelheim's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 175: Bristol-Myers Squibb's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 176: BTG's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 177: Calistoga Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 178: Callisto Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 179: Cambrex's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 180: CanBas’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 181: Cancer Research Technology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 182: Catalyst Biosciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 183: Celgene's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 184: Cell Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 185: Cephalon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 186: Chroma Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 187: CompleGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 188: Compugen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 189: CoNCERT Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 190: Curis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 191: Cyclacel's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 192: Cylene Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 193: Cytokine PharmaSciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 194: Cytopia's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 195: Dainippon Sumitomo Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 196: Deciphera Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 914; Table 197: DeveloGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 198: Dyax's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 199: Eisai's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 200: Elara Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 201: Eli Lilly's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 202: Enkam Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 203: EntreMed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 204: Exelixis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 205: Galapagos’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 206: Genentech's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 207: Generex's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 208: GlaxoSmithKline's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 209: GlycoGenesys’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 210: GPC Biotech's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 211: Hanmi's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 212: Hoffmann-La Roche's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 213: Hutchison China MediTech's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 214: Idera Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 215: ImClone Systems’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 216: ImmunoFrontier's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 217: Incyte Corporation's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 218: Inhibiton Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 219: Inovio's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 220: Insmed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 221: InterMune's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 222: ISU ABXIS’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 223: Johnson & Johnson's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 224: KAI Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 225: Kalypsys’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 226: Keryx Biopharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1057; Table 227: Kiadis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 228: Kirin Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 229: KuDOS’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 230: Lexicon Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 231: Locus Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 232: Lorus Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 233: MaxoCore Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 234: Medisyn Technologies’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 235: Merck & Co's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 236: MethylGene's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 237: Mitsubishi Tanabe Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 238: Molecular LogiX's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 239: NeoPharm's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 240: Nerviano Medical Sciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out1116; Table 241: NicOx's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 242: Nidus Laboratories’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 243: NIH's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 244: Nippon Shinyaku's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 245: Non-industrial Source's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 246: Novartis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 247: Novogen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 248: Oncalis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 249: Onconova's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 250: OncoTherapy Science's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 251: Oncothyreon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 252: OSI Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 253: Pathway Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 254: Peregrine Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 255: Pfizer's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 256: Pharmacyclics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 257: PharmaGap's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 258: PharmaMar's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 259: Pharmexa's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 260: Phytomedics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 261: Piramal's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 262: PIramed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 263: Plexxikon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 264: Provid's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 265: QLT's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 266: Quantum Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 267: Ras Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 268: Reata Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 269: Receptor BioLogix's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 270: Rexahn's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 271: Rigel's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 272: Sanofi-Aventis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 273: Sareum's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 274: SBIO's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 275: Scancell's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 276: Schering-Plough's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 277: Semafore Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 278: Sentinel Oncology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 279: SGX Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 280: Silence Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 281: Sirna Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 282: Sunesis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 283: SuperGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 284: Supratek Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 285: Switch Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 286: Takeda's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 287: Targa Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 288: TargeGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 289: Tekmira Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 290: Telik's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 291: Thallion Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 292: Theryte's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 293: ToolGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 294: TopoTarget's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 295: UCB's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 296: VasGene Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 297: Velacor Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 298: Vertex Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 299: ViroMed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 300: Wyeth's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 301: Xcovery's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out; Table 302: Xencor's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out

Abstract

This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties
Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/15/2012 - 31

Protein Kinase Therapeutics in Oncology - Where to Commercialize?

Table of Contents

Abstract